Alpha 2.0
Login Register
» Authors » Christoph Losem

Christoph Losem

Explore the profile of Christoph Losem including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 711
Followers 0
Related Specialties
Oncology
Hematology
General Medicine
Top 10 Co-Authors
Karin Potthoff
Johanna Harde
Manfred Welslau
Rudolf Weide
Mark-Oliver Zahn
Arnd Nusch
Holger Schulz
Thomas Fietz
Matthias Zaiss
Thomas Wolff
Published In
Eur J Haematol
Leuk Lymphoma
Curr Med Res Opin
Lung Cancer
Ann Hematol
Affiliations
Soon will be listed here.
Recent Articles
1.
Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study
Knauf W, Uhlig J, von der Heyde E, Losem C, Ammon A, Nusch A, et al.
Leuk Lymphoma . 2024 Dec; :1-11. PMID: 39654362
Therapy adherence can significantly influence the outcome of cancer patients. The prospective, non-interventional CARO study (NCT02970747) investigated adherence, effectiveness, and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM)...
2.
Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study
Schwaner I, Kuhn T, Losem C, Wolff T, Otremba B, Zaiss M, et al.
Ann Hematol . 2024 Feb; 103(6):2013-2020. PMID: 38421404
Venetoclax is active in both frontline and relapsed/refractory settings for the treatment of chronic lymphocytic leukemia (CLL). Although the prevalence and severity of tumor lysis syndrome (TLS) are well characterized...
3.
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315)
Sebastian M, Eberhardt W, von der Heyde E, Dorfel S, Wiegand J, Schiefer C, et al.
Int J Cancer . 2024 Feb; 154(11):1967-1978. PMID: 38329180
Patients with lung cancer under treatment have been associated with a high risk of COVID-19 infection and potentially worse outcome, but real-world data on patient-reported outcomes (PROs) are rare. We...
4.
Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR
Gessner C, Fietz T, Losem C, Luck A, Schulz H, Niemeier B, et al.
Curr Med Res Opin . 2022 Sep; 38(12):2191-2199. PMID: 36047998
Objective: Real-world evidence on the application of the granulocyte colony-stimulating factor lipegfilgrastim for the reduction of chemotherapy-induced neutropenia and febrile neutropenia (FN) is limited. The NADIR study aimed to evaluate...
5.
Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study
Jakob A, Zahn M, Nusch A, Werner T, Schnell R, Frank M, et al.
J Bone Oncol . 2022 Mar; 33:100420. PMID: 35340302
Background: In breast cancer and prostate cancer patients, bone metastases (BM) present the main cause of morbidity and often cause debilitating pain, impaired functioning and subsequent deterioration of quality of...
6.
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184]
Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn M, Maintz C, et al.
Lung Cancer . 2021 May; 157:167. PMID: 34049721
No abstract available.
7.
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn M, Maintz C, et al.
Lung Cancer . 2020 Dec; 152:174-184. PMID: 33358484
Objectives: An increasing number of treatment-determining biomarkers has been identified in non-small cell lung cancer (NSCLC) and molecular testing is recommended to enable optimal individualized treatment. However, data on implementation...
8.
Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma
Grohe C, Gleiber W, Haas S, Losem C, Mueller-Huesmann H, Schulze M, et al.
Future Oncol . 2019 Jul; 15(23):2699-2706. PMID: 31282758
To assess outcomes in patients with advanced adenocarcinoma non-small-cell lung cancer who received nintedanib plus docetaxel after progression on prior chemotherapy followed by immune checkpoint inhibitor (ICI) therapy. VARGADO is...
9.
AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany
Zahn M, Linck D, Losem C, Gessner C, Metze H, Gaillard V, et al.
BMC Cancer . 2019 May; 19(1):433. PMID: 31077164
Background: Bevacizumab (Avastin®), a recombinant humanized monoclonal antibody, in combination with platinum-doublet chemotherapy has become a routine treatment for advanced non-small-cell lung cancer (NSCLC). The post-authorization, non-interventional study 'AVAiLABLE' assessed...
10.
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR
Fietz T, Luck A, Schulz H, Harde J, Losem C, Grebhardt S, et al.
Curr Med Res Opin . 2018 Dec; 35(7):1127-1138. PMID: 30557099
The non-interventional study (NIS) NADIR (DRKS00005711) evaluated the effectiveness and safety of prophylaxis with lipegfilgrastim, a glycopegylated granulocyte-colony stimulating factor, in 2500 patients undergoing chemotherapy in routine clinical practice. Primary...